Reference health
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
214/214 checkable references clean · checked 2026-08-06
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
42 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 214 checked references that resolve
resolves10.3389/fmicb.2010.00134
A Brief History of the Antibiotic Era: Lessons Learned and Challenges for the Future
resolves10.1086/595011
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
resolves10.1086/533452
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
resolves10.1128/CMR.00134-14
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
resolves10.1128/AAC.48.1.285-296.2004
Local Variants of Staphylococcal Cassette Chromosome
<i>mec</i>
in Sporadic Methicillin-Resistant
<i>Staphylococcus aureus</i>
and Methicillin-Resistant Coagulase-Negative Staphylococci: Evidence of Horizontal Gene Transfer?
resolves10.1073/pnas.0804178105
Frequent emergence and limited geographic dispersal of methicillin-resistant
<i>Staphylococcus aureus</i>
resolves10.1073/pnas.2204993119
Phylodynamic signatures in the emergence of community-associated MRSA
resolves10.1073/pnas.161272898
The evolution of methicillin resistance in
<i>Staphylococcus aureus</i>
: Similarity of genetic backgrounds in historically early methicillin-susceptible and -resistant isolates and contemporary epidemic clones
resolves10.1086/646432
Methicillin-Resistant
<i>Staphylococcus aureus</i>
in U.S. Hospitals, 1975–1991
resolves10.1128/AAC.45.5.1323-1336.2001
Structural Comparison of Three Types of Staphylococcal Cassette Chromosome
<i>mec</i>
Integrated in the Chromosome in Methicillin-Resistant
<i>Staphylococcus aureus</i>
resolves10.1016/0195-6701(93)90100-E
Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia
resolves10.1001/jama.279.8.593
Community-Acquired Methicillin-Resistant <EMPH TYPE="ITAL">Staphylococcus aureus</EMPH> in Children With No Identified Predisposing Risk
resolves10.1128/JCM.42.10.4735-4743.2004
Genetic Diversity among Community Methicillin-Resistant
<i>Staphylococcus aureus</i>
Strains Causing Outpatient Infections in Australia
resolves10.1073/pnas.1702472114
Origin, evolution, and global transmission of community-acquired
<i>Staphylococcus aureus</i>
ST8
resolves10.1093/infdis/jiv320
Parallel Epidemics of Community-Associated Methicillin-Resistant<i>Staphylococcus aureus</i>USA300 Infection in North and South America
resolves10.1016/S1473-3099(10)70053-0
Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe
resolves10.1128/mBio.01044-14
Origin and Evolution of European Community-Acquired Methicillin-Resistant Staphylococcus aureus
resolves10.1093/cid/ciw532
Evidence for Human Adaptation and Foodborne Transmission of Livestock-Associated Methicillin-Resistant<i>Staphylococcus aureus</i>: Table 1.
resolves10.1128/mBio.01375-16
Evolutionary Dynamics of Pandemic Methicillin-Sensitive
<i>Staphylococcus aureus</i>
ST398 and Its International Spread via Routes of Human Migration
resolves10.1186/s13073-018-0514-9
Detection and analysis of methicillin-resistant human-adapted sequence type 398 allows insight into community-associated methicillin-resistant Staphylococcus aureus evolution
resolves10.1093/ofid/ofy270
Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program
resolves10.1093/cid/ciy512
Long-term Risk of Hemorrhagic Stroke in Patients With Infective Endocarditis: A Danish Nationwide Cohort Study
resolves10.1128/JCM.00798-19
A Multicenter Study To Evaluate Ceftaroline Breakpoints: Performance in an Area with High Prevalence of Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Lineage
resolves10.1099/jmm.0.000585
Borderline oxacillin-resistant Staphylococcus aureus (BORSA) – a more common problem than expected?
resolves10.1016/j.ijmm.2014.06.007
Methicillin resistance in Staphylococcus isolates: The “mec alphabet” with specific consideration of mecC, a mec homolog associated with zoonotic S. aureus lineages
resolves10.1038/s41598-020-69058-z
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
resolves10.1086/427283
Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens
resolves10.1038/s41467-020-15257-1
Ca2+-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids
resolves10.1101/cshperspect.a026997
Mechanism of Action and Resistance to Daptomycin in<i>Staphylococcus aureus</i>and Enterococci
resolves10.1128/AAC.01303-15
Stepwise Decrease in Daptomycin Susceptibility in Clinical Staphylococcus aureus Isolates Associated with an Initial Mutation in
<i>rpoB</i>
and a Compensatory Inactivation of the
<i>clpX</i>
Gene
resolves10.1128/CMR.00188-20
Mobile Oxazolidinone Resistance Genes in Gram-Positive and Gram-Negative Bacteria
resolves10.1056/NEJMoa2300220
Ceftobiprole for Treatment of Complicated
<i>Staphylococcus aureus</i>
Bacteremia
resolves10.1128/AAC.05004-14
Ceftobiprole- and Ceftaroline-Resistant Methicillin-Resistant Staphylococcus aureus
resolves10.1038/s41467-023-38507-4
Efflux pump gene amplifications bypass necessity of multiple target mutations for resistance against dual-targeting antibiotic
resolves10.1128/AAC.02071-15
Penicillin Binding Protein 1 Is Important in the Compensatory Response of Staphylococcus aureus to Daptomycin-Induced Membrane Damage and Is a Potential Target for β-Lactam–Daptomycin Synergy
resolves10.1128/AAC.02483-18
Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
resolves10.2147/IDR.S388354
Association of CRISPR-Cas System with the Antibiotic Resistance and Virulence Genes in Nosocomial Isolates of Enterococcus
resolves10.1371/journal.pone.0030187
Genomic and SNP Analyses Demonstrate a Distant Separation of the Hospital and Community-Associated Clades of Enterococcus faecium
resolves10.1128/mBio.00534-13
Emergence of Epidemic Multidrug-Resistant Enterococcus faecium from Animal and Commensal Strains
resolves10.1038/s41598-020-62371-7
Genomic Epidemiology of Vancomycin-Resistant Enterococcus faecium (VREfm) in Latin America: Revisiting The Global VRE Population Structure
resolves10.1101/gr.204024.116
A decade of genomic history for healthcare-associated <i>Enterococcus faecium</i> in the United Kingdom and Ireland
resolves10.1016/S2666-5247(21)00236-6
The interplay between community and hospital Enterococcus faecium clones within health-care settings: a genomic analysis
resolves10.1186/s13073-021-00868-0
The global dissemination of hospital clones of Enterococcus faecium
resolves10.1128/mbio.03771-21
Genomic Surveillance of Vancomycin-Resistant Enterococcus faecium Reveals Spread of a Linear Plasmid Conferring a Nutrient Utilization Advantage
resolves10.1128/aac.01619-22
Enterococcal Linear Plasmids Adapt to Enterococcus faecium and Spread within Multidrug-Resistant Clades
resolves10.1128/mBio.03284-19
Plasmids Shaped the Recent Emergence of the Major Nosocomial Pathogen Enterococcus faecium
resolves10.1086/587647
Risk of Vancomycin-Resistant<i>Enterococcus</i>(VRE) Bloodstream Infection Among Patients Colonized With VRE
resolves10.1093/ofid/ofab659
Daptomycin-Resistant <i>Enterococcus</i> Bacteremia Is Associated With Prior Daptomycin Use and Increased Mortality After Liver Transplantation
resolves10.1186/s13756-018-0419-9
The importance of adjusting for enterococcus species when assessing the burden of vancomycin resistance: a cohort study including over 1000 cases of enterococcal bloodstream infections
resolves10.1016/j.ijid.2023.04.411
Impact of vancomycin resistance in Enterococcus faecium bloodstream infection on mortality: A retrospective analysis of nationwide surveillance data
resolves10.1017/ice.2021.216
Attributable mortality of vancomycin resistance in ampicillin-resistant
<i>Enterococcus faecium</i>
bacteremia in Denmark and the Netherlands: A matched cohort study
resolves10.1016/j.jhin.2023.09.008
Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis
resolves10.1093/ofid/ofab616
Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I)
resolves10.1093/cid/ciw815
Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients
resolves10.1093/cid/ciz845
Development of Daptomycin Susceptibility Breakpoints for <i>Enterococcus faecium</i> and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute
resolves10.1016/j.jinf.2016.11.004
Daptomycin non-susceptible Enterococcus faecium in leukemia patients: Role of prior daptomycin exposure
resolves10.1371/journal.pone.0209785
Evolution and mutations predisposing to daptomycin resistance in vancomycin-resistant Enterococcus faecium ST736 strains
resolves10.3389/fmicb.2021.749935
Daptomycin Resistance Occurs Predominantly in vanA-Type Vancomycin-Resistant Enterococcus faecium in Australasia and Is Associated With Heterogeneous and Novel Mutations
resolves10.1186/1471-2164-12-512
Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations
resolves10.1128/AAC.46.10.3334-3336.2002
Gene Dosage and Linezolid Resistance in
<i>Enterococcus faecium</i>
and
<i>Enterococcus faecalis</i>
resolves10.1128/AAC.01633-08
Influence of Recombination on Development of Mutational Resistance to Linezolid in
<i>Enterococcus faecalis</i>
JH2-2
resolves10.1093/molbev/msv133
Rampant Parasexuality Evolves in a Hospital Pathogen during Antibiotic Selection
resolves10.1093/jac/dkv420
Tigecycline resistance in clinical isolates of<i>Enterococcus faecium</i>is mediated by an upregulation of plasmid-encoded tetracycline determinants<i>tet</i>(L) and<i>tet</i>(M)
resolves10.1016/j.ijantimicag.2020.106215
In vitro activity of eravacycline and mechanisms of resistance in enterococci
resolves10.1099/ijsem.0.001572
Enterobacter aerogenes Hormaeche and Edwards 1960 (Approved Lists 1980) and Klebsiella mobilis Bascomb et al. 1971 (Approved Lists 1980) share the same nomenclatural type (ATCC 13048) on the Approved Lists and are homotypic synonyms, with consequences for the name Klebsiella mobilis Bascomb et al. 1971 (Approved Lists 1980)
resolves10.1128/CMR.11.4.589
<i>Klebsiella</i>spp. as Nosocomial Pathogens: Epidemiology, Taxonomy, Typing Methods, and Pathogenicity Factors
resolves10.1128/CMR.00079-17
Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae
resolves10.1073/pnas.1501049112
Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in
<i>Klebsiella pneumoniae</i>
, an urgent threat to public health
resolves10.1128/mSphereDirect.00290-17
Whole-Genome Sequencing of Human Clinical Klebsiella pneumoniae Isolates Reveals Misidentification and Misunderstandings of Klebsiella pneumoniae, Klebsiella variicola, and Klebsiella quasipneumoniae
resolves10.3389/fmicb.2019.00044
Multidrug-Resistant Enterobacter cloacae Complex Emerging as a Global, Diversifying Threat
resolves10.1016/S1473-3099(19)30755-8
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study
resolves10.1371/journal.pone.0133727
Genomic Analysis of the Emergence and Rapid Global Dissemination of the Clonal Group 258 Klebsiella pneumoniae Pandemic
resolves10.1038/s41564-019-0492-8
Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread
resolves10.1016/S1473-3099(21)00399-6
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study
resolves10.1093/cid/ciab769
Clones and Clusters of Antimicrobial-Resistant<i>Klebsiella</i>From Southwestern Nigeria
resolves10.3201/eid2504.181482
<i>Klebsiella pneumoniae</i>ST307 with<i>bla</i><sub>OXA-181,</sub>South Africa, 2014–2016
resolves10.1128/mbio.00497-22
Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX
resolves10.1128/mBio.00489-17
Population Genomic Analysis of 1,777 Extended-Spectrum Beta-Lactamase-Producing
<i>Klebsiella pneumoniae</i>
Isolates, Houston, Texas: Unexpected Abundance of Clonal Group 307
resolves10.1016/j.jgar.2020.09.004
Virulence evolution, molecular mechanisms of resistance and prevalence of ST11 carbapenem-resistant Klebsiella pneumoniae in China: A review over the last 10 years
resolves10.1093/jac/dkz446
Evolution of hypervirulence in carbapenem-resistant Klebsiella pneumoniae in China: a multicentre, molecular epidemiological analysis
resolves10.1128/spectrum.01107-22
Recombination Drives Evolution of Carbapenem-Resistant Klebsiella pneumoniae Sequence Type 11 KL47 to KL64 in China
resolves10.3389/fmicb.2019.00542
Diversity, Virulence, and Antimicrobial Resistance in Isolates From the Newly Emerging Klebsiella pneumoniae ST101 Lineage
resolves10.1128/AAC.01148-20
Emerging Antimicrobial-Resistant High-Risk Klebsiella pneumoniae Clones ST307 and ST147
resolves10.1099/jmm.0.000653
Virulence genes in isolates of Klebsiella pneumoniae from the UK during 2016, including among carbapenemase gene-positive hypervirulent K1-ST23 and ‘non-hypervirulent’ types ST147, ST15 and ST383
resolves10.1128/AAC.00519-19
Identification of a Carbapenemase-Producing Hypervirulent Klebsiella pneumoniae Isolate in the United States
resolves10.1038/nmicrobiol.2016.173
The dissemination of multidrug-resistant Enterobacter cloacae throughout the UK and Ireland
resolves10.3201/eid2406.171648
Genomic Epidemiology of Global Carbapenemase-Producing<i>Enterobacter</i>spp., 2008–2014
resolves10.1128/mBio.00542-18
Genomic and Geographic Context for the Evolution of High-Risk Carbapenem-Resistant
<i>Enterobacter cloacae</i>
Complex Clones ST171 and ST78
resolves10.1128/mBio.02093-16
Comprehensive Genome Analysis of Carbapenemase-Producing
<i>Enterobacter</i>
spp.: New Insights into Phylogeny, Population Structure, and Resistance Mechanisms
resolves10.1093/infdis/jiw282
The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace
resolves10.3201/eid2305.162034
Carbapenem-Resistant <i>Enterobacter</i><i>cloacae</i> in Patients from the US Veterans Health Administration, 2006–2015
resolves10.1093/ofid/ofy347
Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program
resolves10.1016/j.cmi.2020.10.016
Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review
resolves10.1093/cid/cix783
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
resolves10.1007/s10096-020-03845-4
Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018
resolves10.1016/S1473-3099(17)30228-1
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
resolves10.1186/s13054-020-2742-9
Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae
resolves10.3389/fcimb.2022.719421
Predictors and Outcomes of Healthcare-Associated Infections Caused by Carbapenem-Nonsusceptible Enterobacterales: A Parallel Matched Case-Control Study
resolves10.1128/AAC.02534-16
Mutations in<i>bla</i><sub>KPC-3</sub>That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases
resolves10.1128/AAC.01694-17
Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae
resolves10.1128/aac.00918-22
<i>In Vitro</i>
Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae
resolves10.1128/spectrum.00084-22
Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China
resolves10.1128/AAC.00198-20
Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in
<i>Enterobacter cloacae</i>
Due to AmpC R2 Loop Deletion
resolves10.1128/aac.01510-23
The metallo-β-lactamases strike back: emergence of taniborbactam escape variants
resolves10.1128/CMR.00040-09
Antibacterial-Resistant<i>Pseudomonas aeruginosa</i>: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms
resolves10.1093/infdis/jiw299
Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections
resolves10.1016/j.ijantimicag.2020.106196
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update
resolves10.1093/gbe/evz119
The Population Structure of Pseudomonas aeruginosa Is Characterized by Genetic Isolation of exoU+ and exoS+ Lineages
resolves10.1093/gbe/evy259
The<i>Pseudomonas aeruginosa</i>Pan-Genome Provides New Insights on Its Population Structure, Horizontal Gene Transfer, and Pathogenicity
resolves10.1111/1758-2229.12653
Environmental reservoirs for
<i>exoS+</i>
and
<i>exoU+</i>
strains of
<i>Pseudomonas aeruginosa</i>
resolves10.1111/j.1469-0691.2007.01939.x
Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa
resolves10.3389/fmicb.2016.01591
Fitness Cost of Fluoroquinolone Resistance in Clinical Isolates of Pseudomonas aeruginosa Differs by Type III Secretion Genotype
resolves10.1093/cid/ciu866
Influence of Virulence Genotype and Resistance Profile in the Mortality of Pseudomonas aeruginosa Bloodstream Infections
resolves10.1097/CCM.0b013e3182377906
Clinical outcomes of type III Pseudomonas aeruginosa bacteremia*
resolves10.1016/j.ebiom.2023.104532
Phylogroup-specific variation shapes the clustering of antimicrobial resistance genes and defence systems across regions of genome plasticity in Pseudomonas aeruginosa
resolves10.1016/j.cmi.2017.06.018
Global emergence of the widespread Pseudomonas aeruginosa ST235 clone
resolves10.1128/mBio.01396-15
The Widespread Multidrug-Resistant Serotype O12 Pseudomonas aeruginosa Clone Emerged through Concomitant Horizontal Transfer of Serotype Antigen and Antibiotic Resistance Gene Clusters
resolves10.1016/S2666-5247(22)00329-9
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study
resolves10.1093/jac/dkg416
Dissemination in distinct Brazilian regions of an epidemiccarbapenem-resistant Pseudomonas aeruginosa producing SPM metallo- -lactamase
resolves10.1093/ofid/ofz273
Extensively Drug-Resistant Pseudomonas aeruginosa ST309 Harboring Tandem Guiana Extended Spectrum β-Lactamase Enzymes: A Newly Emerging Threat in the United States
resolves10.1128/spectrum.04261-22
Epidemiological and Genetic Characteristics of Clinical Carbapenem-Resistant
<i>Pseudomonas aeruginosa</i>
Strains in Guangdong Province, China
resolves10.3390/antibiotics10050548
Retrospective Data Insight into the Global Distribution of Carbapenemase-Producing Pseudomonas aeruginosa
resolves10.1038/s41598-021-00205-w
National surveillance pilot study unveils a multicenter, clonal outbreak of VIM-2-producing Pseudomonas aeruginosa ST111 in the Netherlands between 2015 and 2017
resolves10.1093/cid/ciy378
Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents
resolves10.1093/cid/ciad100
Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli: Results From a Nationwide Study in Italy (ALARICO Network)
resolves10.1007/s40265-013-0168-2
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
resolves10.1128/AAC.00825-15
Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins
resolves10.1186/s12866-019-1522-7
In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
resolves10.1128/AAC.00084-21
<i>In Vitro</i>
Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam
resolves10.1093/cid/ciac097
Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Pneumonia
resolves10.1093/cid/ciaa1909
Evolution of Cefiderocol Non-Susceptibility in<i>Pseudomonas aeruginosa</i>in a Patient Without Previous Exposure to the Antibiotic
resolves10.3390/antibiotics11060723
Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
resolves10.1007/s10096-021-04308-0
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa
resolves10.1016/j.resmic.2011.02.006
Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus–Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU)
resolves10.1086/529198
Antimicrobial Resistance:<i>Acinetobacter baumannii:</i>Epidemiology, Antimicrobial Resistance, and Treatment Options
resolves10.1086/504477
Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa
resolves10.1371/journal.pone.0010034
The Population Structure of Acinetobacter baumannii: Expanding Multiresistant Clones from an Ancestral Susceptible Genetic Pool
resolves10.1128/JCM.43.9.4382-4390.2005
Development of a Multilocus Sequence Typing Scheme for Characterization of Clinical Isolates of
<i>Acinetobacter baumannii</i>
resolves10.3389/fmicb.2019.00930
Comparative Analysis of the Two Acinetobacter baumannii Multilocus Sequence Typing (MLST) Schemes
resolves10.1128/mbio.02759-21
Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance
resolves10.1128/JCM.00619-11
Molecular Epidemiology of Carbapenem-Nonsusceptible Acinetobacter baumannii in the United States
resolves10.1080/22221751.2022.2093134
Epidemiological and genetic characteristics of clinical carbapenem-resistant
<i>Acinetobacter baumannii</i>
strains collected countrywide from hospital intensive care units (ICUs) in China
resolves10.1128/spectrum.02463-22
Genomic Analysis of Carbapenem-Resistant Acinetobacter baumannii Strains Recovered from Chilean Hospitals Reveals Lineages Specific to South America and Multiple Routes for Acquisition of Antibiotic Resistance Genes
resolves10.1007/s13205-018-1310-3
Molecular characterization of carbapenemases of clinical Acinetobacter baumannii–calcoaceticus complex isolates from a University Hospital in Tunisia
resolves10.1093/jac/dkz055
Using WGS to identify antibiotic resistance genes and predict antimicrobial resistance phenotypes in MDR Acinetobacter baumannii in Tanzania
resolves10.1128/AAC.02190-17
Distribution and Molecular Characterization of Acinetobacter baumannii International Clone II Lineage in Japan
resolves10.1093/jac/dkq223
A 63 kb genomic resistance island found in a multidrug-resistant Acinetobacter baumannii isolate of European clone I from 1977
resolves10.1128/mSphere.00117-16
IncM Plasmid R1215 Is the Source of Chromosomally Located Regions Containing Multiple Antibiotic Resistance Genes in the Globally Disseminated Acinetobacter baumannii GC1 and GC2 Clones
resolves10.1111/j.1469-0691.2005.01320.x
Cephalosporinase over-expression resulting from insertion of ISAba1 in Acinetobacter baumannii
resolves10.1016/j.ijid.2022.12.010
Geographic patterns of Acinetobacter baumannii and carbapenem resistance in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2019
resolves10.1016/j.ijantimicag.2015.03.001
Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii : Mechanisms and epidemiology
resolves10.1016/j.ijantimicag.2012.09.008
Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages
resolves10.1097/CCM.0000000000000125
Risk Factors and Outcome Analysis of Acinetobacter baumannii Complex Bacteremia in Critical Patients*
resolves10.1017/ice.2019.296
Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015–2017
resolves10.1186/s13054-016-1392-4
Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis
resolves10.1093/cid/ciad094
Navigating Available Treatment Options for Carbapenem-Resistant<i>Acinetobacter baumannii-calcoaceticus</i>Complex Infections
resolves10.1093/cid/ciad428
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
resolves10.1128/AAC.00093-17
<i>In Vitro</i>
Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
resolves10.1128/AAC.01221-20
Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3
resolves10.1128/AAC.00877-21
Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii
resolves10.1016/S1473-3099(20)30796-9
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
resolves10.1038/nmicrobiol.2017.104
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
resolves10.1016/S1473-3099(23)00184-6
Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)
resolves10.1128/AAC.04808-14
Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii
resolves10.1128/AAC.02243-16
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
resolves10.1093/ofid/ofad500.2476
2893 A. Efficacy and Safety of Aztreonam-Avibactam for the Treatment of Serious Infections Due to Gram-Negative Bacteria, Including Metallo-β-Lactamase-Producing Pathogens: Phase 3 REVISIT Study
resolves10.1128/AAC.02529-16
WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent “β-Lactam Enhancer” Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones
resolves10.1128/AAC.01963-19
VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in
<i>Enterobacterales</i>
and Pseudomonas aeruginosa
resolves10.3389/fmicb.2021.697180
QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics
resolves10.1093/jac/dkad060
Gepotidacin: a novel, oral, ‘first-in-class’ triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea
resolves10.1016/S0140-6736(23)02196-7
Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials
resolves10.1128/aac.00054-22
Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020
resolves10.1128/AAC.00708-15
TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced
<i>In Vivo</i>
Efficacy against Methicillin-Resistant Staphylococcus aureus
resolves10.1128/AAC.00250-20
Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid
resolves10.1021/jm9001764
Inhibition of Staphyloxanthin Virulence Factor Biosynthesis in <i>Staphylococcus aureus</i>: In Vitro, in Vivo, and Crystallographic Results
resolves10.1126/scitranslmed.3003021
Treatment and Prevention of Urinary Tract Infection with Orally Active FimH Inhibitors
resolves10.1097/SLA.0000000000004102
A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI)
resolves10.1172/JCI136577
Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis
resolves10.1016/j.jvacx.2022.100168
Vaccines for healthcare associated infections without vaccine prevention to date
resolves10.1016/S2666-5247(22)00303-2
The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline
resolves10.1016/S0140-6736(21)02724-0
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
resolves10.1016/S2542-5196(21)00280-1
Global antibiotic consumption and usage in humans, 2000–18: a spatial modelling study
resolves10.1128/AAC.42.11.3049
Historical Yearly Usage of Glycopeptides for Animals and Humans: The American-European Paradox Revisited
resolves10.1093/ofid/ofy293
Antimicrobial Susceptibility of Acinetobacter calcoaceticus–Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016)
resolves10.1093/ofid/ofy344
Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997–2016
resolves10.1093/ofid/ofy343
Geographic and Temporal Patterns of Antimicrobial Resistance in Pseudomonas aeruginosa Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997–2016
resolves10.1186/s12864-020-07041-8
Benchmarking hybrid assembly approaches for genomic analyses of bacterial pathogens using Illumina and Oxford Nanopore sequencing
resolves10.1093/femsre/fuaa025
Experimental approaches to tracking mobile genetic elements in microbial communities
The 42 references without a DOI — listed, not checked
no DOI — not checkedPfizer. Antimicrobial Testing Leadership and Surveillance. ATLAS https://www.atlas-surveillance.com (2024).
no DOI — not checkedUS Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019 (CDC, 2019).
no DOI — not checkedEuropean Centre for Disease Prevention and Control. European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC www.ecdc.europa.eu/en/about-us/networks/disease-networks-and-laboratory-networks/ears-net-data (2023).
no DOI — not checkedUS Centers for Disease Control and Prevention. COVID-19: US impact on antimicrobial resistance, special report 2022 (CDC, 2022).
no DOI — not checkedHamidian, M. & Nigro, S. J. Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii. Microb. Genom. 5, e000306 (2019).
no DOI — not checkedHolt, K. et al. Five decades of genome evolution in the globally distributed, extensively antibiotic-resistant Acinetobacter baumannii global clone 1. Microb. Genom. 2, e000052 (2016).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04959344 (2022).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT03687255 (2020).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT03840148 (2024).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04979806 (2023).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT03931876 (2019).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04243863 (2022).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT03491748 (2020).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05204368 (2023).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT03182504 (2018).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04380207 (2022).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05072444 (2022).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05590728 (2024).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT03747497 (2022).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05369052 (2024).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04532957 (2024).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05507463 (2024).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05685615 (2023).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04020341 (2023).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05630833 (2023).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04649541 (2023).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05137314 (2022).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04808414 (2022).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04865393 (2024).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT03723551 (2023).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04160468 (2023).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04596319 (2024).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04684641 (2023).
no DOI — not checkedS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05010577 (2023).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05776004 (2024).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT03638830 (2021).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05331885 (2023).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT03816956 (2023).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04763759 (2024).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05274802 (2022).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT05138822 (2023).
no DOI — not checkedUS National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT02469857 (2021).
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-08-06 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1038/s41579-024-01054-w"><img src="https://citestamp.com/citestamped/10.1038/s41579-024-01054-w/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1038/s41579-024-01054-w)